AstraZeneca (AZN,AZN.L,ZEG.DE,AZN.ST) said the FDA's Oncologic Drugs Advisory Committee or ODAC has recognised a favourable benefit risk profile for AstraZeneca's Truqap in combination with abiraterone and androgen deprivation therapy for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, based on the CAPItello-281 Phase III trial. The Committee voted 7 to 1, with 1 abstaining.
In August 2025, the FDA accepted the sNDA for Truqap in combination with abiraterone and ADT. The ODAC provides the FDA with independent, expert advice on marketed and investigational medicines for use in the treatment of cancer. The FDA will consider the feedback as it reviews the submission.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.